



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David M. Markovitz, *et al.*
Serial No.: 10/670,065
Filed: 09/24/03
Entitled: **Methods of Secretory Vimentin Detection and Modulation**
Group No.: 1645
Examiner: Cook

**INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 13, 2006.

By: 

Mary Ellen Waite


Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: July 13, 2006


David A. Casimir
Registration No. 42,395

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David M. Markovitz, *et al.*
Serial No.: 10/670,065
Filed: 09/24/03
Entitled: **Methods of Secretary Vimentin Detection and Modulation**
Group No.: 1645
Examiner: Cook

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- WO 98/39298
- WO 05/012872 A2
- DT 1810423
- Traub, P. *Intermediate Filaments A Review*, (Springer-Verlag, New York, Tokyo, 1985).
- Fuchs, E. & Weber, K. Intermediate filaments: structure, dynamics, function, and disease. *Annu Rev Biochem* **63**, 345-82 (1994).
- Christian, J.L., Edelstein, N.G. & Moon, R.T. Overexpression of wild-type and dominant negative mutant vimentin subunits in developing *Xenopus* embryos. *New Biol* **2**, 700-11. (1990).

- Colucci-Guyon, E. *et al.* Mice lacking vimentin develop and reproduce without an obvious phenotype. *Cell* **79**, 679-94. (1994).
- Eckes, B. *et al.* Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. *J Cell Sci* **111**, 1897-907 (1998).
- Galou, M. *et al.* Disrupted glial fibrillary acidic protein network in astrocytes from vimentin knockout mice. *J Cell Biol* **133**, 853-63. (1996).
- Eckes, B. *et al.* Impaired wound healing in embryonic and adult mice lacking vimentin. *J Cell Sci* **113**, 2455-62 (2000).
- Cain, H., Kraus, B., Krauspe, R., Osborn, M. & Weber, K. Vimentin filaments in peritoneal macrophages at various stages of differentiation and with altered function. *Virchows Arch B Cell Pathol Incl Mol Pathol* **42**, 65-81 (1983).
- Rius, C., Cabanas, C. & Aller, P. The induction of vimentin gene expression by sodium butyrate in human promonocytic leukemia U937 cells. *Exp Cell Res* **188**, 129-34 (1990).
- Rius, C. & Aller, P. Vimentin expression as a late event in the in vitro differentiation of human promonocytic cells. *J Cell Sci* **101**, 395-401 (1992).
- Reddy, V.Y., Zhang, Q.Y. & Weiss, S.J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. *Proc Natl Acad Sci U S A* **92**, 3849-53 (1995).
- Punturieri, A. *et al.* Regulation of Elastinolytic Cysteine Proteinase Activity in Normal and Cathepsin K-deficient Human Macrophages. *J Exp Med* **192**, 789-800 (2000).
- Cain, H., Krauspe, R. & Kraus, B. The cytoskeleton in activated and in functionally disordered cells of the macrophage system. *Pathol Res Pract* **175**, 162-79 (1982).
- Gao, Y. & Sztul, E. A novel interaction of the Golgi complex with the vimentin intermediate filament cytoskeleton. *J Cell Biol* **152**, 877-94. (2001).
- Traub, P. Large scale isolation, purification, and partial characterization of the intermediate filament-specific, Ca²⁺-activated proteinase from porcine kidney and Ehrlich ascites tumor cells: a comparative study. *Arch Biochem Biophys* **228**, 120-32. (1984).

- Traub, P., Scherbarth, A., Willingale-Theune, J., Paulin-Levasseur, M. & Shoeman, R. Differential sensitivity of vimentin and nuclear lamins from Ehrlich ascites tumor cells toward Ca^{2+} -activated neutral thiol proteinase. *Eur J Cell Biol* **46**, 478-90. (1988).
- Yoshida, H., Murachi, T. & Tsukahara, I. Degradation of actin and vimentin by calpain II, a Ca^{2+} -dependent cysteine proteinase, in bovine lens. *FEBS Lett* **170**, 259-62. (1984).
- Perides, G., Kuhn, S., Scherbarth, A. & Traub, P. Probing of the structural stability of vimentin and desmin-type intermediate filaments with Ca^{2+} -activated proteinase, thrombin and lysine-specific endoproteinase Lys-C. *Eur J Cell Biol* **43**, 450-8. (1987).
- Tozser, J. *et al.* Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. *Eur J Biochem* **265**, 423-9. (1999).
- Ben-Ze'ev, A., Babiss, L.E. & Fisher, P.B. Cleavage of vimentin in dense cell cultures. Inhibition upon transformation by type 5 adenovirus. *Exp Cell Res* **166**, 47-62. (1986).
- Belin, M.T. & Boulanger, P. Processing of vimentin occurs during the early stages of adenovirus infection. *J Virol* **61**, 2559-66. (1987).
- Cheng, T.J. & Lai, Y.K. Identification of mitogen-activated protein kinase-activated protein kinase-2 as a vimentin kinase activated by okadaic acid in 9L rat brain tumor cells. *J Cell Biochem* **71**, 169-81. (1998).
- Turowski, P., Myles, T., Hemmings, B.A., Fernandez, A. & Lamb, N.J. Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. *Mol Biol Cell* **10**, 1997-2015 (1999).
- Yasui, Y. *et al.* Protein kinases required for segregation of vimentin filaments in mitotic process. *Oncogene* **20**, 2868-76. (2001).
- Lo, C.-J., Fu, M. & Cryer, H.G. Interleukin 10 Inhibits Alveolar Macrophage Production of Inflammatory Mediators Involved in Adult Respiratory Distress Syndrome. *Journal of Surgical Research* **79**, 179-184 (1998).
- Bhattacharyya, S., Ghosh, S., Jhonson, P.L., Bhattacharya, S.K. & Majumdar, S. Immunomodulatory Role of Interleukin-10 in Visceral Leishmaniasis: Defective Activation of Protein Kinase C-Mediated Signal Transduction Events. *Infect. Immun.* **69**, 1499-1507 (2001).

- Bogdan, C., Vodovotz, Y. & Nathan, C. Macrophage deactivation by interleukin 10. *J Exp Med* **174**, 1549-55. (1991).
- Schlosser-Silverman, E., Elgrably-Weiss, M., Rosenshine, I., Kohen, R. & Altuvia, S. Characterization of Escherichia coli DNA lesions generated within J774 macrophages. *J Bacteriol* **182**, 5225-30 (2000).
- Klymkowsky, M.W., Bachant, J.B. & Domingo, A. Functions of intermediate filaments. *Cell Motil Cytoskeleton* **14**, 309-31 (1989).
- Lehto, V.P., Hovi, T., Vartio, T., Badley, R.A. & Virtanen, I. Reorganization of cytoskeletal and contractile elements during transition of human monocytes into adherent macrophages. *Lab Invest* **47**, 391-9 (1982).
- c
- Chu, J.J. *et al.* Taxol induces concomitant hyperphosphorylation and reorganization of vimentin intermediate filaments in 9L rat brain tumor cells. *J Cell Biochem* **68**, 472-83. (1998).
- Szalay, J. *et al.* Associations of PKC isoforms with the cytoskeleton of B16F10 melanoma cells. *J Histochem Cytochem* **49**, 49-66. (2001).
- Shoeman, R.L. *et al.* Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. *Proc Natl Acad Sci U S A* **87**, 6336-40. (1990).
- Kontny, E., Kurowska, M., Szczepanska, K. & Maslinski, W. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. *J Leukoc Biol* **67**, 249-58. (2000).
- Hansson, G.K., Lagerstedt, E., Bengtsson, A. & Heideman, M. IgG binding to cytoskeletal intermediate filaments activates the complement cascade. *Exp Cell Res* **170**, 338-50 (1987).
- Sanchez, A., Ossorio, C., Alvaro-Gracia, J.M., Padilla, R. & Avila, J. A subset of antibodies from the sera of patients with systemic lupus erythematosus react with vimentin and DNA. *J Rheumatol* **17**, 205-9 (1990).
- Senecal, J.L. & Rauch, J. Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNA-binding activity. *Arthritis Rheum* **31**, 864-75 (1988).


- Franch, A., Castellote, C., Vila, J.L., Vilaro, S. & Castell, M. Anticytoskeletal autoantibody development in adjuvant arthritis. *J Rheumatol* **21**, 489-97 (1994).
- Lane, B.R. *et al.* TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. *J Immunol* **163**, 3653-61 (1999).
- Terasaki, M. & Reese, T.S. Characterization of endoplasmic reticulum by co-localization of BiP and dicarbocyanine dyes. *J Cell Sci* **101**, 315-22. (1992).
- Matsukawa, A. *et al.* Pivotal role of the CC chemokine, macrophage-derived chemokine, in the innate immune response. *J Immunol* **164**, 5362-8 (2000).
- Cherry *et al.*, Enzyme-Linked Fluorescent Detection For Automated Multiplex DNA Sequencing, *Genomics* **20**, 68074 (1994)
- Schmitt *et al.*, Expression of Gene 1.2 and Gene 10 of Bacteriophage T7 Is Lethal to F Plasmid-Containing *Escherichia coli*, *J of Bacteriology* **173**, 1536-1543 (1991)
- Slilaty *et al.*, Accurate insertional inactivation of *lacZa*: construction of pTrueBlue and M13TrueBlue cloning vectors, *Gene* **213**, 83-91 (1998)
- Henrich *et al.*, Use of the *l*ysis gene of bacteriophage ϕ X174 for the construction of a positive selection vector, *Gene* **42**, 345-349 (1986)
- Viera *et al.*, The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers, *Gene* **19**, 259-268 (1982)
- Quandt *et al.*, Versatile suicide vectors which allow direct selection for gene replacement in Gram-negative bacteria, *Gene* **127**, 15-21 (1993)
- Wiemann *et al.*, Simultaneous On-Line DNA Sequencing on Both Strands with Two Fluorescent Dyes, *Analytical Biochemistry* **224**, 117-121 (1995)
- Bernard *et al.*, Positive-selection vectors using the F plasmid *ccdB* killer gene, *Gene* **148**, 71-74 (1994)
- Dillard *et al.*, Analysis of *Streptococcus pneumoniae* Sequences Cloned into *Escherichia coli*: Effect of Promoter Strength and Transcription Terminators, *J of Bacteriology* **173**, 5105-5109 (1991)
- Geider *et al.*, A plasmid cloning system utilizing replication and packaging functions of the filamentous bacteriophage ϕ d, *Gene* **33**, 341-349 (1985)

- Smith et al., fluorescence detection in automated DNA sequence analysis, *Nature* 321, 674-679 (1986)
- Reynolds et al., Parameters Affecting Transcription Termination by *Escherichia coli* RNA Polymerase, *J Mol Biol* 224, 31-51 (1992)
- Hoffmann-Berling, *Virology* 22, 305-313 (1964)
- Church et al., Multiplex DNA Sequencing, *Science* 240, 185-188 (1988)
- Prober et al., A System for Rapid DNA Sequencing with Fluorescent Chain-Terminating Dideoxynucleotides, *Science* 238, 336-341 (1987)
- Wiemann et al., "Doublex" Fluorescent DNA Sequencing: Two Independent Sequences Obtained Simultaneously in One Reaction with Internal Labeling and Unlabeled Primers, *Analytical Biochemistry* 234, 166-174 (1996)
- Egholm et al., PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules, *Nature* 365, 566-568 (1993)
- Sanger et al., DNA sequencing with chain-terminating inhibitors, *PNAS* 74, 5463-5467 (1977)
- Lipman et al., A tool for multiple sequence alignment, *PNAS* 86, 4412-4415 (1989)
- Fitzgerald et al., Rapid shotgun cloning utilizing the two base recognition endonucleases CviJ1, *Nucleic Acids Research* 20, 3753-3762 (1992)
- Rose, *Nucleic Acids Research* 16, 355 (1988)
- Tabor et al., A single residue in DNA polymerases of the *Escherichia coli* DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides, *PNAS* 92, 6339-6343 (1995)
- Chen et al., Cloning of *Streptococcus pneumoniae* DNA fragments in *Escherichia coli* requires vectors protected by strong transcriptional terminators, *Gene* 55, 179-187 (1987)
- Bolivar et al., Construction and Characterization of New Cloning Vehicles, *Gene* 2, 95-113 (1977)
- Liu et al., An Efficient Method for Blunt-End Ligation of PCR Products, *Biotechniques* 12, 28-29 (1992)

- Creasey et al., Application of a Novel Chemiluminescence-Based DNA Detection Method to Single-Vector and Multiplex DNA Sequencing, *BioTechniques* 11, 102-109 (1991)
- Neurath et al., Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice, *J of Ex Med* 182, 1281-1290 (1995)
- Chen et al., Construction and properties of a new insertion vector, pJDC9, that is protected by transcriptional terminators and useful for cloning of DNA from *Streptococcus pneumoniae*, *Gene* 64, 155-164 (1988)
- Podor et al., Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface, *J. Biol Chem* 277(9):7529 (2002)
- Perides et al., Electrostatic and hydrophobic interactions of the intermediate filament protein vimentin and its amino terminus with lipid bilayers, *J Biol Chem* 262:13742-13749 (1987)
- Nishimura et al., A di-acidic signal required for selective export from the endoplasmic reticulum, *Science* 277:556-559 (1997)
- Nishimura et al., A di-acidic (DXE) code directs concentration of cargo during export from the endoplasmic reticulum, *J Biol Chem* 274:15937-15946 (1999)
- Hansson et al., Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells, *PNAS USA* 81:3103-3107 (1984)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 7/13/06


David A. Casimir
Registration No. 42,395
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/670,065
		Filing Date	9/24/2003
		First Named Inventor	Markovitz et al.
		Art Unit	
		Examiner Name	
Sheet 2 of 8	Attorney Docket Number		UM-08388

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Traub, P. Intermediate Filaments A Review, (Springer-Verlag, New York, Tokyo, 1985).	
	4	Fuchs, E. & Weber, K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63, 345-82 (1994).	
	5	Christian, J.L., Edelstein, N.G. & Moon, R.T. Overexpression of wild-type and dominant negative mutant vimentin subunits in developing Xenopus embryos. New Biol 2, 700-11. (1990).	
	6	Colucci-Guyon, E. et al. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell 79, 679-94. (1994).	
	7	Eckes, B. et al. Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci 111, 1897-907 (1998).	
	8	Galou, M. et al. Disrupted glial fibrillary acidic protein network in astrocytes from vimentin knockout mice. J Cell Biol 133, 853-63. (1996).	
	9	Eckes, B. et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 113, 2455-62 (2000).	
	10	Cain, H., Kraus, B., Krauspe, R., Osborn, M. & Weber, K. Vimentin filaments in peritoneal macrophages at various stages of differentiation and with altered function. Virchows Arch B Cell Pathol Incl Mol Pathol 42, 65-81 (1983).	
	11	Rius, C., Cabanas, C. & Aller, P. The induction of vimentin gene expression by sodium butyrate in human promonocytic leukemia U937 cells. Exp Cell Res 188, 129-34 (1990).	
	12	Rius, C. & Aller, P. Vimentin expression as a late event in the in vitro differentiation of human promonocytic cells. J Cell Sci 101, 395-401 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/670,065
		Filing Date	9/24/2003
		First Named Inventor	Markovitz et al.
		Art Unit	
		Examiner Name	
Sheet	4	of	8
		Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	Belin, M.T. & Boulanger, P. Processing of vimentin occurs during the early stages of adenovirus infection. J Virol 61, 2559-66. (1987).	
	24	Cheng, T.J. & Lai, Y.K. Identification of mitogen-activated protein kinase-activated protein kinase-2 as a vimentin kinase activated by okadaic acid in 9L rat brain tumor cells. J Cell Biochem 71, 169-81. (1998).	
	25	Turowski, P., Myles, T., Hemmings, B.A., Fernandez, A. & Lamb, N.J. Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. Mol Biol Cell 10, 1997-2015 (1999).	
	26	Yasui, Y. et al. Protein kinases required for segregation of vimentin filaments in mitotic process. Oncogene 20, 2868-76. (2001).	
	27	Lo, C.-J., Fu, M. & Cryer, H.G. Interleukin 10 Inhibits Alveolar Macrophage Production of Inflammatory Mediators Involved in Adult Respiratory Distress Syndrome. Journal of Surgical Research 79, 179-184 (1998).	
	28	Bhattacharyya, S., Ghosh, S., Jhonson, P.L., Bhattacharya, S.K. & Majumdar, S. Immunomodulatory Role of Interleukin-10 in Visceral Leishmaniasis: Defective Activation of Protein Kinase C-Mediated Signal Transduction Events. Infect. Immun. 69, 1499-1507 (2001).	
	29	Bogdan, C., Vodovotz, Y. & Nathan, C. Macrophage deactivation by interleukin 10. J Exp Med 174, 1549-55. (1991).	
	30	Schlosser-Silverman, E., Elgrably-Weiss, M., Rosenshine, I., Kohen, R. & Altuvia, S. Characterization of Escherichia coli DNA lesions generated within J774 macrophages. J Bacteriol 182, 5225-30 (2000).	
	31	Klymkowsky, M.W., Bachant, J.B. & Domingo, A. Functions of intermediate filaments. Cell Motil Cytoskeleton 14, 309-31 (1989).	
	32	Lehto, V.P., Hovi, T., Vartio, T., Badley, R.A. & Virtanen, I. Reorganization of cytoskeletal and contractile elements during transition of human monocytes into adherent macrophages. Lab Invest 47, 391-9 (1982).	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/670,065
		Filing Date	9/24/2003
		First Named Inventor	Markovitz et al.
		Art Unit	
		Examiner Name	
Sheet 8	of 8	Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	73	Podor et al., Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface, J. Biol Chem 277(9):7529 (2002)	
	74	Perides et al., Electrostatic and hydrophobic interactions of the intermediate filament protein vimentin and its amino terminus with lipid bilayers, J Biol Chem 262:13742-13749 (1987)	
	75	Nishimura et al., A di-acidic signal required for selective export from the endoplasmic reticulum, Science 277:556-559 (1997)	
	76	Nishimura et al., A di-acidic (DXE) code directs concentration of cargo during export from the endoplasmic reticulum, J Biol Chem 274:15937-15946 (1999)	
	77	Hansson et al., Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells, PNAS USA 81:3103-3107 (1984)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.